Replacing centrifugation with mixing in urine analysis enriches protein pool in the urine samples

Garbicz, Damian; Pilžys, Tomaš; Wiśniowski, Iga; Grzesiuk, Małgorzata; Cylke, Radosław; Kosieradzki, Maciej; Grzesiuk, Elżbieta; Piwowarski, Jan; Marcinkowski, Michał; Lisik, Wojciech

doi:10.1016/j.ab.2021.114284

Cited by 1 publication

(2 citation statements)

References 91 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They concluded that new biomarkers were more likely to be found using whole urine samples without centrifugation. 153 However, the sample size used in the above studies was too small to draw strong conclusions.…”

Section: Screening Strategy Of Urine Biomarkersmentioning

confidence: 95%

“…applied Western blotting and mass spectrometry techniques to investigate differences in proteins between uncentrifuged whole urine, urine pellets and supernatants and found that whole urine contained more proteins than urine supernatant. They concluded that new biomarkers were more likely to be found using whole urine samples without centrifugation 153 . However, the sample size used in the above studies was too small to draw strong conclusions.…”

Section: Challenges Of Urine‐based Liquid Biopsy In Blcamentioning

confidence: 98%

See 1 more Smart Citation

Urine‐based liquid biopsy in bladder cancer: Opportunities and challenges

Wang

Jin

et al. 2023

Clinical and Translational Dis

View full text Add to dashboard Cite

Bladder cancer (BLCA) is a most common urological tumours with high rate of recurrence, which needs long‐term of follow‐up. To date, diagnosis and surveillance of BLCA still rely on cystoscopy, an invasive and expensive method that increases the difficulty for routine follow‐up. Therefore, exploring new biomarkers or tests is an effective way to improve the current clinical management of BLCA. Recent years, liquid biopsy has received increasing attention, especially for its great potential for clinical application in the non‐invasive detection of tumours. In addition, liquid biopsy involves a wide range of biomarkers, including DNA, RNA, proteins, extracellular vesicles and metabolites in blood, urine or other body fluids. For BLCA, urine is a most ideal body fluid to achieve non‐invasive diagnosis and surveillance. Here, we address recent developments of urine‐based biomarkers or tests for clinical diagnostic challenges in BLCA, such as early detection, minimal residual, recurrence monitoring and therapeutic response. Meanwhile, the many challenges of urine biomarkers that need to be overcome are also discussed.

show abstract

Section: Screening Strategy Of Urine Biomarkersmentioning

confidence: 95%

Section: Challenges Of Urine‐based Liquid Biopsy In Blcamentioning

confidence: 98%